Pharmaceuticals

C&Y Pharmaceutical

C&Y Pharmaceutical released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 173.8 M, actual EPS CNY 0.0135

C&Y Pharmaceutical FY2026 Q1 Earnings Release on April 28 After-Market (BJT)

C&Y Pharmaceutical FY2025 Annual Earnings Release on April 28, 2026 After-Market BJT

C&Y Pharmaceutical released FY2025 9 Months earnings on October 29 After-Market (BJT), actual revenue CNY 611.47 M, actual EPS CNY 0.0857

C&Y Pharmaceutical released FY2025 Q3 earnings on October 29 After-Market BJT, actual revenue CNY 238.48 M, actual EPS CNY 0.0854

C&Y Pharmaceutical to Release FY2025 Q3 Earnings on October 30 After-Market (BJT)

C&Y Pharmaceutical released FY2025 Q2 earnings on August 25 After-Market (BJT), actual revenue CNY 191.26 M, actual EPS CNY -0.0426

C&Y Pharmaceutical released FY2025 Semi-Annual Earnings on August 25 After-Market (BJT), Actual Revenue CNY 373M, Actual EPS CNY 0.0016

C&Y Pharmaceutical to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Qianyuan Pharmaceutical Secretary Responds to Investors About Smoking Cessation and Allergy Medication Market Performance

Qianyuan Medicine's Subsidiary Obtains Approval for Ebastine API

Qianyuan Pharmaceutical's Secretary Responds to Investor Questions on Overseas Expansion Plans and Technical Barriers for Smoking Cessation Medication

Qianyuan Medicine's Net Profit Down 43.17% in Q1 2025

C&Y Pharmaceutical released FY2025 Q1 earnings on April 18 After-Market (BJT), actual revenue CNY 181.74 M, actual EPS CNY 0.043

C&Y Pharmaceutical released FY2024 earnings on April 14 After-Market (BJT), actual revenue CNY 846.61 M, actual EPS CNY 0.1743

C&Y Pharmaceutical released FY2024 Q4 earnings on April 14 After-Market (BJT), actual revenue CNY 237.79 M, actual EPS CNY -0.0081

C&Y Pharmaceutical to Release FY2025 Q1 Earnings on April 19 After-Market BJT

Qianyuan Pharmaceutical Secretary Responds to Impact of Trump's Tariff Policy on Company

C&Y Pharmaceutical to Release FY2024 Annual Earnings on April 15 After-Market BJT

Qianyuan Pharmaceutical 2024 Annual Performance Forecast: Net Profit Expected to Increase by 58.76%-106.39%

300254

C&Y Pharmaceutical announced that the revenue for the third quarter was 238 million yuan, a year-on-year increase of 14.82%; the net profit was 21.9466 million yuan, a year-on-year increase of 106.06%. The revenue for the first three quarters was 611 million yuan, a year-on-year increase of 0.44%; the net profit was 22.3274 million yuan, a year-on-year decrease of 49.43%

Zhitong

C&Y Pharmaceutical: Net profit in the third quarter was 21.9466 million yuan, a year-on-year increase of 106.06%

According to the Zhitong Finance APP, C&Y Pharmaceutical announced that its shareholder Weng Zhanguo plans to reduce his holdings in the company by no more than 7.6831 million shares (not exceeding 3% of the company's total share capital) through centralized bidding and block trading from November 13, 2025, to February 12, 2026

C&Y Pharmaceutical shareholder Weng Zhanguo plans to reduce his holdings by no more than 3%

On the evening of September 15th, C&Y Pharmaceutical announced that the company will carry out financing lease sale-leaseback business, using part of its fixed assets to apply for financing of no more than 50 million yuan from Ping An Dian Chuang International Financial Leasing Co., Ltd., with a term of 2 and a half years

C&Y Pharmaceutical: Launching a financing lease sale-leaseback business not exceeding 50 million yuan

300086

002022

301211

002030

002370

The hepatitis concept sector saw a short-term surge, with KHB hitting the limit up, and C&Y Pharmaceutical, BIOCAUSE HEILEN PHARMA, DAJY, Yatai pharm, and Honz all rising

Honz

BIOCAUSE HEILEN PHARMA

DAJY

Yatai pharm

The hepatitis concept sector has seen a short-term surge

According to the Zhitong Finance APP, C&Y Pharmaceutical disclosed the draft of the 2025 Restricted Stock Incentive Plan, which proposes to grant a total of no more than 9.15 million restricted shares to the incentive recipients, accounting for 3.68% of the company's total share capital at the time of the announcement of this incentive plan draft. Among them, 7.95 million shares will be granted in the first grant, with a total of 171 incentive recipients, and the grant price (including reserves) is set at 5.60 yuan/share

C&Y Pharmaceutical plans to launch a restricted stock incentive plan of no more than 9.15 million shares

688799

603716

002550

600513

36Kr learned that as of the time of publication, the innovative drug concept has repeatedly strengthened, Qianhong Bio-pharma surged and hit the limit up, Thalys, JLPC, C&Y Pharmaceutical, and Haizhi Ke all reached the limit up, while HWPC rose over 10%, setting a new historical high for its stock price

36Kr

HWPC

Thalys

Qianhong Bio-pharma

JLPC

The innovative drug concept has repeatedly strengthened, and Qianhong Bio-pharma has surged to the limit

C&Y Pharmaceutical announced that its subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration to market the raw material drug Ebastine. This medication is suitable for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria. The original manufacturer of Ebastine is INDUSTRIAS FARMACEUTICAS ALMIRALL, S.A., and the Ebastine tablets produced by its subsidiary Hangzhou C&Y Pharmaceutical Co., Ltd. have passed the consistency evaluation and have been included in the National Medical Insurance Catalog Category B

C&Y Pharmaceutical: Ebastine raw material drug approved for market launch

300723

002437

002422

300204

The chemical pharmaceutical sector saw a short-term surge, with ApicHope rising over 10%, followed by GLORIA PHARMA, KELUN PHARMA, Staidson BioPharm, C&Y Pharmaceutical, and Kexin Pharmaceutical

ApicHope

GLORIA PHARMA.

KELUN PHARMA

Staidson BioPharm

Keyuan Pharma

The chemical pharmaceutical sector has seen a short-term surge, with ApicHope rising over 10%

C&Y Pharmaceutical released its Q1 2025 performance report, with operating revenue of 182 million yuan, a year-on-year decrease of 4.09%. The net profit attributable to the parent company was 10.3904 million yuan, a year-on-year decline of 43.17%; the net profit after deducting non-recurring gains and losses was 2.7904 million yuan, a year-on-year decrease of 82.48%. The basic earnings per share were 0.043 yuan

C&Y Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 10.3904 million yuan, a decrease of 43.17%

According to the Zhitong Finance APP, C&Y Pharmaceutical released its 2024 annual report, stating that the company's operating income was 847 million yuan, a year-on-year increase of 5.92%. The net profit attributable to shareholders of the listed company was 42.1901 million yuan, a year-on-year increase of 67.45%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25.2287 million yuan. The basic earnings per share were 0.1746 yuan

C&Y Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 42.1901 million yuan, an increase of 67.45%

C&Y Pharmaceutical(300254.SZ)